Broad Label Gives Tesaro's Niraparib A Head Start In Ovarian Cancer
Executive Summary
Tesaro takes opportunity of broad approval for Zejula (niraparib) in recurrent ovarian cancer to highlight franchise expansion opportunities in other tumor types, including PD-1 inhibitor combination studies.